Charles River Laboratories International Inc. (NYSE:CRL) has earned a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the company. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $86.14.

Several research analysts have recently issued reports on CRL shares. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a research note on Wednesday. Credit Suisse Group AG started coverage on shares of Charles River Laboratories International in a research note on Monday, June 20th. They issued a “neutral” rating and a $84.00 target price on the stock. Evercore ISI reiterated a “hold” rating and issued a $91.50 target price (up previously from $83.50) on shares of Charles River Laboratories International in a research note on Thursday, August 4th. Citigroup Inc. upped their target price on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Thursday, August 4th. Finally, Jefferies Group upped their target price on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, August 4th.

Charles River Laboratories International (NYSE:CRL) traded down 0.98% on Friday, reaching $82.48. 123,441 shares of the company traded hands. The stock’s 50-day moving average is $82.38 and its 200-day moving average is $82.63. The stock has a market capitalization of $3.90 billion, a price-to-earnings ratio of 27.86 and a beta of 1.14. Charles River Laboratories International has a 1-year low of $61.91 and a 1-year high of $89.18.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.10 by $0.10. Charles River Laboratories International had a net margin of 9.49% and a return on equity of 25.18%. The business had revenue of $434.10 million for the quarter, compared to analyst estimates of $425.05 million. During the same quarter in the previous year, the firm posted $0.96 earnings per share. Charles River Laboratories International’s quarterly revenue was up 27.8% on a year-over-year basis. Equities research analysts expect that Charles River Laboratories International will post $4.46 EPS for the current year.

In other Charles River Laboratories International news, Chairman James C. Foster sold 18,351 shares of the business’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $85.63, for a total transaction of $1,571,396.13. Following the sale, the chairman now directly owns 383,283 shares in the company, valued at $32,820,523.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Davide Molho sold 7,877 shares of the business’s stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $84.10, for a total transaction of $662,455.70. The disclosure for this sale can be found here. Company insiders own 2.30% of the company’s stock.

A number of hedge funds have recently modified their holdings of CRL. Renaissance Technologies LLC raised its stake in shares of Charles River Laboratories International by 8.9% in the first quarter. Renaissance Technologies LLC now owns 950,209 shares of the company’s stock worth $72,159,000 after buying an additional 77,700 shares during the period. HBK Investments L P acquired a new stake in shares of Charles River Laboratories International during the first quarter worth about $1,350,000. Bogle Investment Management L P DE acquired a new stake in shares of Charles River Laboratories International during the first quarter worth about $249,000. Geode Capital Management LLC raised its stake in shares of Charles River Laboratories International by 11.9% in the first quarter. Geode Capital Management LLC now owns 302,940 shares of the company’s stock worth $23,004,000 after buying an additional 32,224 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Charles River Laboratories International by 45.0% in the first quarter. Goldman Sachs Group Inc. now owns 545,510 shares of the company’s stock worth $41,426,000 after buying an additional 169,376 shares during the period. Institutional investors own 96.19% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.